Defence Therapeutics Announces Grant of Restricted Stock Units
Montreal, Quebec--(Newsfile Corp. - April 24, 2026) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC), ("Defence" or the "Company"), a publicly traded biotechnology and precision intracellular drug-delivery company, wishes to announce that the board of directors of the Company approved the grant of 200,000 incentive restricted stock units ("RSUs") to Mr. Sebastien Plouffe, CEO and Director of the Company, vesting immediately. Each RSU entitles the
Biotechnologies, Pharmaceutique, Santé
2026-04-24 6:30 PM EDT | Defence Therapeutics Inc.
Herbal Dispatch Reports Q4 2025 Gross Sales of $6.2 Million, Achieves Positive Adjusted EBITDA, and Reports Full Year Gross Sales of $16.5 Million
Vancouver, British Columbia--(Newsfile Corp. - April 24, 2026) - Herbal Dispatch Inc. (CSE: HERB) (OTCQB: LUFFF) (FSE: HA9) ("Herbal Dispatch" or the "Company"), announces its financial results for the fourth quarter and year ended December 31, 2025. Q4 2025 HIGHLIGHTS Gross sales of $6.2 million, representing a 115% increase compared to $2.9 million in Q4 2024 Net revenue of $4.1 million (excluding excise
Pharmaceutique, Cannabis, Dispensaires de cannabis
2026-04-24 3:01 AM EDT | Herbal Dispatch Inc.
Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Series
King of Prussia, Pennsylvania--(Newsfile Corp. - April 23, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer. Phio announced today that Mr. Robert Bitterman, CEO and Chairman of the Board, Phio Pharmaceuticals will provide an overview of the Company's INTASYL siRNA platform and discuss recent clinical progress and priorities,
Biotechnologies, Soins de santé et hôpitaux, Pharmaceutique, Santé
2026-04-23 7:00 AM EDT | Phio Pharmaceuticals Corp.
Optimi Health Files LIFE Offering Document in Connection with NASDAQ Listing
Vancouver, British Columbia--(Newsfile Corp. - April 23, 2026) - Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN) (the "Company" or "Optimi"), a commercial-stage pharmaceutical manufacturer of regulated psychedelic drug products, today announced that further to its press release dated March 16, 2026, it intends to complete a portion of its previously announced offering of common shares (the "Offering") in Canada pursuant to the Listed Issuer Financing Exemption c
Biotechnologies, Pharmaceutique, Santé, Psychédéliques
2026-04-23 7:00 AM EDT | Optimi Health Corp.
Herbal Dispatch Welcomes the Honourable Herb Dhaliwal as Full-Time Chairman
Vancouver, British Columbia--(Newsfile Corp. - April 23, 2026) - Herbal Dispatch Inc. (CSE: HERB) (OTCQB: LUFFF) (FSE: HA9) ("Herbal Dispatch" or the "Company"), a leading cannabis e-commerce and distribution platform, is pleased to announce the appointment of the Honourable Herb Dhaliwal, PC, as a full-time Board Member and Chairman of the Board. The Honourable Herb Dhaliwal, brings a wealth of experience in public service, business, and leadership to Her
Pharmaceutique, Cannabis, Dispensaires de cannabis
2026-04-23 3:01 AM EDT | Herbal Dispatch Inc.
Unbuzzd Wellness Appoints Richard Buzbuzian as CEO to Lead Nationwide Commercialization of Innovative, Clinically Validated Hangover Remedy and Alcohol Metabolism Accelerant
Vancouver, British Columbia--(Newsfile Corp. - April 22, 2026) - Unbuzzd Wellness Inc. (the "Company" or "Unbuzzd"), the company behind unbuzzdTM ("unbuzzd") — the scientifically-proven and game-changing beverage proven to accelerate alcohol metabolism, restore mental clarity and reduce hangover symptoms, is pleased to announce the appointment of Mr. Richard Buzbuzian as Chief Executive Officer. This marks a pivotal milestone in the Company's commer
2026-04-22 9:01 AM EDT | Unbuzzd Wellness Inc.
PreveCeutical Announces Non-Brokered Private Placement
Vancouver, British Columbia--(Newsfile Corp. - April 22, 2026) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H0) (the "Company" or "PreveCeutical"), is pleased to announce a non-brokered private placement (the "Offering") of up to 40,000,000 units (each, a "Unit") in the capital of the Company at a price of $0.
Biotechnologies, Pharmaceutique, Santé
2026-04-22 3:00 AM EDT | PreveCeutical Medical Inc.
Gregory Esemplare Appointed Chief Operating Officer of HarmonyRx
New York, New York--(Newsfile Corp. - April 21, 2026) - HarmonyRx today announced the appointment of Gregory Esemplare as Chief Operating Officer (COO). In this role, Greg will oversee operations across the organization, with a focus on driving alignment, enhancing execution and supporting continued growth in pharmacy benefits. Greg brings extensive experience in healthcare services, pharmacy benefits and client-focused operations. He previously served in a senior le
2026-04-21 8:25 AM EDT | HarmonyRx
PharmaTher Highlights Strategic Ketamine Opportunity Following New U.S. Executive Order on Psychedelic Treatments for Serious Mental Illness
Toronto, Ontario--(Newsfile Corp. - April 21, 2026) - PharmaTher Holdings Ltd. (OTCQB: PHRRF) (CSE: PHRM) ("PharmaTher" or the "Company"), a specialty pharmaceutical company, today announced that it believes the recent U.S. executive order, "Accelerating Medical Treatments
Biotechnologies, Pharmaceutique
2026-04-21 8:00 AM EDT | PharmaTher Holdings Ltd.
Herbal Dispatch Announces Receipt of U.S. DTC Eligibility and Engagement of Market Maker
Vancouver, British Columbia--(Newsfile Corp. - April 21, 2026) - Herbal Dispatch Inc. (CSE: HERB) (OTCQB: LUFFF) (FSE: HA9) ("Herbal Dispatch" or the "Company"), a leading cannabis e-commerce and distribution platform, is pleased to announce that the Company's common shares are now eligible for electronic clearing and settlement through the Depository Trust Company ("DTC"). DTC eligibility significantly enhances accessibility for U.S.-based investor
Pharmaceutique, Cannabis, Dispensaires de cannabis
2026-04-21 3:01 AM EDT | Herbal Dispatch Inc.
Richards Group Inc. Announces April 2026 Dividend
Toronto, Ontario--(Newsfile Corp. - April 20, 2026) - Richards Group Inc. (TSX: RIC) (the "Company") announced today its cash dividend for the month ended April 30, 2026 of Cdn$0.11 per share. This dividend will be to shareholders of record at the close of business on April 30, 2026 and will be payable on May 14, 2026. Shareholders who are non-residents of Canada may be required to pay all withholding taxes payable in respect of any dividends of income by the Company, whether such dividends
Soins de santé et hôpitaux, Produits ménagers / de consommation / cosmétiques, Pharmaceutique
2026-04-20 10:24 AM EDT | Richards Group Inc.
Nextleaf Advances Capex-Light Model with New Micro-Processing Site Licence, Supporting Revenue Growth and Margin Expansion
Vancouver, British Columbia--(Newsfile Corp. - April 20, 2026) - Nextleaf Solutions Ltd. (CSE: OILS) (OTCQB: OILFF) (FSE: L0MA) ("Nextleaf", "OILS", or the "Company"), a multi-patented life science company and Canadian cannabis processor, is pleased to announce it has been granted a Health Canada Micro-Processing Licence for its second site of operations, Nextleaf Distribution. The issuance of this licence marks a key milestone in the Company's capex-light expansion strategy stre
Biotechnologies, Pharmaceutique, Cannabis, Extracteurs de cannabis
2026-04-20 9:00 AM EDT | Nextleaf Solutions Ltd.
PharmaTher's Microneedle Patch Platforms Positioned to Benefit from Major U.S. Catalysts in Psychedelics and Peptides
Toronto, Ontario--(Newsfile Corp. - April 20, 2026) - PharmaTher Holdings Ltd. (OTCQB: PHRRF) (CSE: PHRM) ("PharmaTher" or the "Company"), a specialty pharmaceutical comp
Biotechnologies, Pharmaceutique
2026-04-20 8:00 AM EDT | PharmaTher Holdings Ltd.
Optimi Health Launches Ibogaine Initiative as U.S. Executive Order Signals Pathway for Psychedelic Drug Products
Vancouver, British Columbia--(Newsfile Corp. - April 20, 2026) - Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN) (the "Company" or "Optimi"), a commercial-stage pharmaceutical manufacturer of regulated psychedelic drug products, today launched its Ibogaine Initiative, a program to extend the Company's Health Canada-licensed GMP platform to include the manufacture and supply of ibogaine. The initiative comes as the United States has, for the first time, taken ini
Biotechnologies, Pharmaceutique, Santé, Psychédéliques
2026-04-20 6:00 AM EDT | Optimi Health Corp.
Optimi Health startet Ibogaine-Initiative, da US-Executive Order einen Weg für psychedelische Arzneimittelprodukte signalisiert
Vancouver, British Columbia--(Newsfile Corp. - Montag, 20. April 2026) - Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN) (das "Unternehmen" oder "Optimi"), ein kommerziell tätiger pharmazeutischer Hersteller regulierter psychedelischer Arzneimittelprodukte, gab heute den Start seiner Ibogaine-Initiative bekannt. Ziel des Programms ist es, die nach GMP lizenzierte Plattform des Unternehmens mit Health-Canada-Zulassung auf die Herstellung und Lieferung von Ibogaine auszuwe
Biotechnologies, Pharmaceutique, Santé, Psychédéliques
2026-04-20 2:00 AM EDT | Optimi Health Corp.
Unbuzzd Wellness Announces Resignation of Chief Executive Officer
Vancouver, British Columbia--(Newsfile Corp. - April 17, 2026) - Unbuzzd Wellness Inc. (the "Company" or "Unbuzzd"), the company behind unbuzzd™,the scientifically-proven beverage proven to accelerate alcohol metabolism, restore mental clarity, and reduce hangover symptoms, announces today that John Duffy has resigned from his position as Chief Executive Officer of the Company, effective as of the date hereof. The Company thanks Mr. Duffy for his contributions and wi
2026-04-17 5:00 PM EDT | Unbuzzd Wellness Inc.
PharmaTher Supports Proposed U.S. Peptide Reclassification, Reinforcing the Strategic Value of Its Microneedle Patch Platforms for Peptide Delivery
Toronto, Ontario--(Newsfile Corp. - April 16, 2026) - PharmaTher Holdings Ltd. (OTCQB: PHRRF) (CSE: PHRM) ("PharmaTher" or the "Company"), a specialty pharmaceutical company focused on microneedle patch technologies and peptide-enabled product oppor
Biotechnologies, Pharmaceutique
2026-04-16 8:00 AM EDT | PharmaTher Holdings Ltd.
Medexus Provides Business Update on GRAFAPEX (treosulfan) for Injection, Capital Allocation, and Investor Conference Participation
Ontario and Chicago, Illinois--(Newsfile Corp. - April 15, 2026) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) today provided an operational business update on the ongoing commercialization of GRAFAPEX™ (treosulfan) for Injection in the United States and on certain recent capital allocation and capital structure developments and announced company management's participation in two upcoming investor conferences. All dollar amounts in this news release are in US dollars unle
Biotechnologies, Soins de santé et hôpitaux, Pharmaceutique, Santé
2026-04-15 5:30 PM EDT | Medexus Pharmaceuticals Inc.
Patient Safety Must Remain the Foundation of Scope of Practice Decisions in Canada
Ottawa, Ontario--(Newsfile Corp. - April 15, 2026) - As scope of practice expansion is actively being considered across Canada, the Canadian Ophthalmological Society (COS) is emphasizing that patient safety must remain the central and non-negotiable principle guiding any changes to healthcare delivery. While COS supports innovation and system modernization, it is deeply concerned that several proposed changes would expand independent clinical authority to non-physician providers without
Soins de santé et hôpitaux, Pharmaceutique, Santé
2026-04-15 12:05 PM EDT | Canadian Ophthalmological Society (COS)
La sécurité des patients doit demeurer le fondement des décisions relatives au champ de pratique au Canada
Ottawa, Ontario--(Newsfile Corp. - 15 avril 2026) - Alors que l'élargissement des champs de pratique est activement envisagé à travers le Canada, la Société canadienne d'ophtalmologie (SCO) rappelle que la sécurité des patients doit demeurer le principe central et non négociable guidant toute évolution de la prestation des soins de santé. Bien que la SCO appuie l'innovation et la modernisation du système, elle demeure profondém
Soins de santé et hôpitaux, Pharmaceutique, Santé
2026-04-15 12:05 PM EDT | Canadian Ophthalmological Society (COS)